Methods for treating subject with DAGE derived peptides

• US 6,297,050 B1
• Filed: 05/28/1999
• Issued: 10/02/2001
• Est. Priority Date: 09/30/1994
• Status: Expired due to Fees

• Current Assignee: Ludwig Institute for Cancer Research, Ltd.
• Original Assignee: Ludwig Institute for Cancer Research, Ltd.
• Inventors: Ikeda, Hideyuki, Boon-Falleur, Thierry, Coulie, Pierre
• Primary Examiner(s): Bansal, Geetha P.
• Assistant Examiner(s): Canella, Karen A.
• Application Number:
  US09/322,360
• Time in Patent Office: 858 Days
• Field of Search: 514/2, 514/21, 530/300, 530/328, 530/329, 435/325, 435/355, 435/372, 435/372.3
• US Class Current: 435/372.3
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: Y10S 530/828 Cancer

Abstract

A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as DAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described.

Claims

1. A method for stimulating a cytotoxic T-cell response, comprising adding a peptide, whose sequence is set forth in SEQ ID NO:

17, to a sample containing T-cells and cells expressing HLA molecules in an amount sufficient to bind to the HLA molecules on the surface of cells in said sample and to stimulate a cytotoxic T-cell response against complexes of said HLA molecule and said peptide, wherein said peptide consists of the amino acids sequence set forth at;

amino acids 28-36 of SEQ ID NO;

17;

amino acids 40-48 of SEQ ID NO;

17;

amino acids 48-56 of SEQ ID NO;

17;

amino acids 80-88 of SEQ ID NO;

17;

amino acids 100-108 of SEQ ID NO;

17;

amino acids 118-126 of SEQ ID NO;

17;

amino acids 150-158 of SEQ ID NO;

17;

amino acids 156-164 of SEQ ID NO;

17;

amino acids 184-192 of SEQ ID NO;

17;

amino acids 195-203 of SEQ ID NO;

17;

amino acids 198-206 of SEQ ID NO;

17;

amino acids 204-212 of SEQ ID NO;

17;

amino acids 254-262 of SEQ ID NO;

17;

amino acids 355-364 of SEQ ID NO;

17;

amino acids 375-383 of SEQ ID NO;

17;

amino acids 447-455 of SEQ ID NO;

17;

or

the amino acid sequence set forth in SEQ ID NO;

5.

2. The method of claim 1, wherein said HLA molecule is an HLA-A2 molecule, and said peptide consists of amino acids 100-108 of SEQ ID NO:

17, amino acids 355-364 of SEQ ID NO;

17.

3. The method of claim 1, wherein said HLA molecule is HLA-A3 molecule, and said peptide consists of amino acids 28-36 of SEQ ID NO:

17, amino acids 80-88 of SEQ ID NO;

17;

or amino acids 118-126 of SEQ ID NO;

17.

4. The method of claim 1, wherein said HLA molecule is an HLA-A11 molecule, and said peptide consists of amino acids 150-158 of SEQ ID NO:

17, amino acids 195-203 of SEQ ID NO;

17;

or amino acids 204-212 of SEQ ID NO;

17.

5. The method of claim 1, wherein said HLA molecule is HLA-A24, and said peptide has the amino acid sequence of SEQ ID NO:

5, amino acids 254-262 of SEQ ID NO;

17;

or amino acids 447-455 of SEQ ID NO;

17.

6. The method of claim 1, wherein said HLA molecule is HLA-B7, and said peptide consists of amino acids 48-56 of SEQ ID NO:

17.

7. The method of claim 1, wherein said HLA molecule is HLA-B8, and said peptide consists of amino acids 156-164 of SEQ ID NO:

17;

or amino acids 198-206 of SEQ ID NO;

17.

8. The method of claim 1, wherein said HLA molecule is HLA-B44, and said peptide consists of amino acids 184-192 of SEQ ID NO:

17.

9. The method of claim 1, wherein said HLA molecule is HLA-Cw* 1601, and said peptide consists of amino acids 40-48 of SEQ ID NO:

17;

or amino acids 375-383 of SEQ ID NO;

17.

10. An isolated cytolytic T cell which specifically recognizes a complex of an HLA molecule and a peptide, wherein said peptide is selected from the group of peptides consisting of:

amino acids 28-36 of SEQ ID NO;

17;

amino acids 40-48 of SEQ ID NO;

17;

amino acids 48-56 of SEQ ID NO;

17;

amino acids 80-88 of SEQ ID NO;

17;

amino acids 100-108 of SEQ ID NO;

17;

amino acids 118-126 of SEQ ID NO;

17;

amino acids 150-158 of SEQ ID NO;

17;

amino acids 156-165 of SEQ ID NO;

17;

amino acids 184-192 of SEQ ID NO;

17;

amino acids 195-203 of SEQ ID NO;

17;

amino acids 198-206 of SEQ ID NO;

17;

amino acids 204-212 of SEQ ID NO;

17;

amino acids 254-262 of SEQ ID NO;

17;

amino acids 355-364 of SEQ ID NO;

17;

amino acids 375-383 of SEO ID NO;

17;

amino acids 447-455 of SEQ ID NO;

17;

or

the amino acid sequence set forth in SEO ID NO;

5.

11. The isolated cytolytic T cell of claim 10, specific for complexes of an HLA-B7 molecule and a peptide consisting of amino acids 48-56 of SEQ ID NO:

17.

12. The isolated cytolytic T cell of claim 10, specific for complexes of an HLA-B8 molecule and a peptide consisting of amino acids 156-164 of SEQ ID NO:

17, or amino acids 198-206 of SEQ ID NO;

17.

13. The isolated cytolytic T cell of claim 10, specific for a complex of an HLA-B44 molecule and a peptide consisting of amino acids 184-192 of SEQ ID NO:

17.

14. The isolated cytolytic T cell of claim 10, specific for complexes of an HLA-Cw* 1601 molecule and a peptide consisting of amino acids 40-48 of SEQ ID NO:

17, or amino acids 375-383 of SEQ ID NO;

17.

15. The isolated cytolytic T cell of claim 10, specific for a complex of an HLA-A2 molecule and a peptide consisting of amino acids 100-108 of SEQ ID NO:

17, or amino acids 355-364 of SEQ ID NO;

17.

16. The isolated cytolytic T cell of claim 10, specific for a complex of an BLA-A3 molecule and a peptide consisting of amino acids 28-36 of SEQ ID NO:

17, amino acids 80-88 of SEQ ID NO;

17;

or amino acids 118-126 of SEQ ID NO;

17.

17. The isolated cytolytic T cell of claim 16, specific for a complex of an HLA-A11 molecule and a peptide consisting of amino acids 150-158 of SEQ ID NO:

17, amino acids 195-203 of SEQ ID NO;

17;

or amino acids 204-212 of SEQ ID NO;

17.

18. The isolated cytolytic T cell of claim 10, specific for a complex of an HLA-A24 molecule and a peptide consisting of SEQ ID NO:

5, amino acids 195-203 of SEQ ID NO;

17;

or amino acids 204-212 of SEQ ID NO;

17.

19. An isolated peptide, the amino acid sequence of which consists of:

amino acids 28-36 of SEQ ID NO;

17;

amino acids 40-48 of SEQ ID NO;

17;

amino acids 48-56 of SEQ ID NO;

17;

amino acids 80-88 of SEQ ID NO;

17;

amino acids 100-108 of SEQ ID NO;

17;

amino acids 118-126 of SEQ ID NO;

17;

amino acids 150-158 of SEQ ID NO;

17;

amino acids 156-164 of SEQ ID NO;

17;

amino acids 184-192 of SEQ ID NO;

17;

amino acids 195-203 of SEQ ID NO;

17;

amino acids 198-206 of SEQ ID NO;

17;

amino acids 204-212 of SEQ ID NO;

17;

amino acids 254-262 of SEQ ID NO;

17;

amino acids 355-364 of SEQ ID NO;

17;

amino acids 375-383 of SEQ ED NO;

17;

or

amino acids 447-455 of SEQ ID NO;

17.